Why Science? | Advanced Cell Therapy and Research Institute Singapore

Official ACTRIS pages describe a national and regional centre supporting discovery, process development, manufacturing, clinical services, commercialisation and training for cellular therapies. Its facility serves investigational and clinical-use work under controlled systems.

Living cells are both the therapeutic product and a changing biological system. Identity, viability, potency, purity and sterility must be controlled while preserving the function that treatment requires. The practical capability is institutional literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “ACTRIS supports advanced-therapy translation and manufacture” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Institutional capability does not establish safety or efficacy for any therapy.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Next chapter

Cell therapies may replace, repair or direct biological function. Because cells respond to their environment and can change over time, product attributes include viability and function as well as molecular identity.

Cell-therapy manufacturing links donor or patient material, collection, processing, culture, formulation, storage and administration through a chain of identity and custody. One broken link can compromise safety or interpretation. The practical capability is cell-therapy literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Cells can be the therapeutic product” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A cell type name does not fully define a manufactured therapy.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Autologous products begin with material from the patient who will receive them, while allogeneic products use another donor or source. Logistics, scale, immune compatibility and release timing differ. Each pathway creates distinct risks and advantages.

Process development turns a research method into a controlled manufacturing procedure. Closed systems, trained operators, environmental controls and in-process checks reduce variation without eliminating biological complexity. The practical capability is therapy-model reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Autologous and allogeneic pathways differ” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: One manufacturing model is not universally better.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Apheresis, tissue or other starting material varies with donor, patient, collection, transport and time. Acceptance criteria and sampling protect downstream work. Clinical scheduling and manufacturing capacity must align for time-sensitive material.

GMP records make each batch reconstructable. Deviations, equipment, materials, test results and authorised release decisions stay attached to the product because manufacturing evidence is part of patient protection. The practical capability is starting-material literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Collection quality enters the process” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Manufacturing cannot always correct poor starting material.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Identifiers, labels, electronic systems and witnessed steps connect the person, starting material, intermediate containers and final product. Custody records show who controlled each handoff. Reconciliation catches missing or conflicting information.

Living cells are both the therapeutic product and a changing biological system. Identity, viability, potency, purity and sterility must be controlled while preserving the function that treatment requires. The practical capability is traceability reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Chain of identity and custody protect the patient” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A readable label alone is not a complete identity-control system.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Teams define steps, ranges, materials, equipment, sampling and controls that can produce consistent product. Small experiments explore sensitivity before scale or automation. The process should preserve critical quality attributes and fit clinical timelines.

Cell-therapy manufacturing links donor or patient material, collection, processing, culture, formulation, storage and administration through a chain of identity and custody. One broken link can compromise safety or interpretation. The practical capability is process-development literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Process development converts a research method” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A successful academic protocol is not automatically GMP-ready.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Separation methods enrich or remove cell populations, while signals may activate cells for expansion or function. Marker panels and functional tests track change. Reagents and timing can affect phenotype and variability.

Process development turns a research method into a controlled manufacturing procedure. Closed systems, trained operators, environmental controls and in-process checks reduce variation without eliminating biological complexity. The practical capability is cell-processing reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Cell selection and activation shape the product” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Surface-marker identity does not by itself establish therapeutic potency.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Vectors or editing systems can introduce, remove or alter genetic information. Efficiency, copy number, off-target change, residual materials and long-term behaviour may matter. Controls match the technology and intended product.

GMP records make each batch reconstructable. Deviations, equipment, materials, test results and authorised release decisions stay attached to the product because manufacturing evidence is part of patient protection. The practical capability is gene-modification literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Genetic modification adds capability and risk” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A successful genetic edit in sampled cells does not describe every cell or future effect.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Culture conditions, media, density, vessels, duration and stimulation affect growth and phenotype. More cells are useful only when identity, viability and function remain within defined limits. Scale changes gas, nutrients and mixing.

Living cells are both the therapeutic product and a changing biological system. Identity, viability, potency, purity and sterility must be controlled while preserving the function that treatment requires. The practical capability is cell-culture reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Expansion must preserve function” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A high cell count does not prove product quality.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Closed processing limits contact with the environment and can support repeatability. Automation standardises selected steps while equipment setup, alarms and maintenance still need trained oversight. Connections and transfers remain potential failure points.

Cell-therapy manufacturing links donor or patient material, collection, processing, culture, formulation, storage and administration through a chain of identity and custody. One broken link can compromise safety or interpretation. The practical capability is manufacturing-systems literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Closed and automated systems can reduce exposure” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Closed equipment does not eliminate contamination or operator risk.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Current Good Manufacturing Practice governs people, premises, equipment, materials, documents, production, testing and quality oversight. Batch records capture actual execution. Approved procedures and change control protect consistency.

Process development turns a research method into a controlled manufacturing procedure. Closed systems, trained operators, environmental controls and in-process checks reduce variation without eliminating biological complexity. The practical capability is GMP literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “GMP makes the process controlled and reconstructable” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: GMP compliance does not prove clinical benefit.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Many cell products cannot undergo terminal sterilisation, so clean environments, qualified processes, gowning, monitoring and aseptic technique are critical. Risk assessment targets interventions and open steps. Contamination control spans facility and behaviour.

GMP records make each batch reconstructable. Deviations, equipment, materials, test results and authorised release decisions stay attached to the product because manufacturing evidence is part of patient protection. The practical capability is aseptic-processing literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Aseptic processing manages contamination risk” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A cleanroom classification does not guarantee a sterile batch.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Counts, viability, phenotype, metabolites, transduction or other measures can confirm progression and trigger decisions. Sampling consumes product and may not represent every container. Limits should connect to process understanding and final attributes.

Living cells are both the therapeutic product and a changing biological system. Identity, viability, potency, purity and sterility must be controlled while preserving the function that treatment requires. The practical capability is process-control reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “In-process controls guide the batch” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: An in-process pass does not replace final release testing.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

A potency assay measures a relevant function or surrogate tied to mechanism of action. Complex products may require more than one assay. Variability, reference materials and assay range affect interpretation.

Cell-therapy manufacturing links donor or patient material, collection, processing, culture, formulation, storage and administration through a chain of identity and custody. One broken link can compromise safety or interpretation. The practical capability is potency-assay literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Potency links the product to intended biological activity” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: One laboratory function may not predict clinical response.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Identity, purity, potency, viability, sterility, endotoxin and residuals may be relevant depending on the product. Some microbial tests take longer than the clinical window, requiring justified strategies and controls. Quality units authorise release.

Process development turns a research method into a controlled manufacturing procedure. Closed systems, trained operators, environmental controls and in-process checks reduce variation without eliminating biological complexity. The practical capability is quality-control literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Release testing balances safety, quality and timing” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A preliminary result is not the same as authorised product release.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Freezing, storage, transport, thawing and administration can change viability and function. Temperature records, validated shippers and instructions connect manufacturing with clinical care. Deviations require assessment before use.

GMP records make each batch reconstructable. Deviations, equipment, materials, test results and authorised release decisions stay attached to the product because manufacturing evidence is part of patient protection. The practical capability is cold-chain reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Cryopreservation and clinical handoff preserve the therapy” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A product that left the facility within specification may change during transport or thaw.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Archive patient or donor codes, custody, materials, equipment, process version, operators, environment, in-process data, genetic modification, deviations, QC assays, release, storage, transport and administration handoff. Students can study workflows safely while qualified teams control clinical manufacture.

Living cells are both the therapeutic product and a changing biological system. Identity, viability, potency, purity and sterility must be controlled while preserving the function that treatment requires. The practical capability is advanced-therapy career preparation. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. ACTRIS and its authorised clinical and manufacturing partners control current facilities, products and released results; ethics bodies, regulators, sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Keep a cell-therapy manufacturing evidence receipt” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Only current authorised teams and responsible authorities can release, administer or approve a therapy.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter